From: Therapeutic advancement of chronic lymphocytic leukemia
Reference (year) | Regimen | Phase | Number of patients | Treatment status | CR,% | ORR,% | Median PFS (months) | Median OS (months) |
---|---|---|---|---|---|---|---|---|
Hillmen, 2007 [25] | Alemtuzumab | 3 | 149 | Untreated | 24 | 83 | 14.6 | NR |
 | Chlorambucil |  | 148 | Untreated | 2 | 55 | 11.7 | NR |
Gritti, 2012 [27] | Alemtuzumab | 2 | 18 | F-ref | 8 | 44 | 10.3 | 29.1 |
Stilgenbauer, 2011 [28] | AD | 2 | 30 | Untreated, del(17p) | 20 | 97 | 16.9 | >24 , NR |
 |  | 17 | Relapse, del(17p) | 0 | 76 | 10.4 | 15 | |
 |  | 40 | F-ref | 5 | 70 | 8.4 | 12 | |
Geisler, 2011 [29] | AFC | 3 | 129 | Untreated, high-risk | 57 | 88 | 37 | NR |
 | FC |  | 133 | Untreated, high-risk | 45 | 80 | 31 | NR |
Badoux, 2011 [30] | CFAR | 2 | 80 | Refractory /relapse | 29 | 65 | 10.6 | N/A |
Zent, 2011 [31] | PAR | 2 | 19 | Refractory /relapse | 32 | 74 | 7 | 23 |